Fundraising FoxHillhouse Capital — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Hong Kong-listed, Suzhou-headquartered biopharmaceutical company developing antibody therapeutics with in-house biomanufacturing.
Suzhou, CN
Xueming Qian(Executive Director, Chairman and CEO)in
Co-investorsARCH Venture PartnersChina Structural Reform FundFortune Venture CapitalLilly Asia VenturesQatar Investment AuthorityTemasek
XPENG develops smart electric vehicles, including AI-powered SUVs and coupes, along with related mobility technology spanning road and air travel.
AI & Machine LearningHardwareMobility & Transportation
Xiaopeng He(Founder)in
Co-investorsCoatue ManagementEast West Ventures EWVGranite AsiaPrimavera Venture Management LimitedShunwei CapitalWelight Capital+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.